Form 4: Intra-Cellular Therapies Director Receives Stock Options and Restricted Stock Units

Eduardo Rene Salas, a director at Intra-Cellular Therapies, Inc., was granted stock options and restricted stock units on June 14, 2024.

Summary

• Eduardo Rene Salas, a director of Intra-Cellular Therapies, Inc. [ITCI], filed a Form 4 on June 18, 2024.
• On June 14, 2024, Salas was granted 2,951 restricted stock units (RSUs) and 4,322 stock options.
• The RSUs vest on June 14, 2025, which is the first anniversary of the grant date.
• The stock options have an exercise price of $67.77, are exercisable from June 14, 2025, and expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation practice. It's neither overwhelmingly positive nor negative.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules and exercise prices are generally aligned with industry norms to encourage long-term value creation.

Stakeholder Impact

• The grant of stock options and restricted stock units can incentivize the director to work towards increasing shareholder value.

Key Dates